Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IART
Integra LifeSciences Holdings Corporation (IART) P/E ratio
Integra LifeSciences Holdings Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3,430× (December 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 52.1× | 102.04% |
| FY2022 | 25.8× | (23.77%) |
| FY2021 | 33.8× | (17.89%) |
| FY2020 | 41.2× | (58.99%) |
| FY2019 | 100× | 60.42% |
| FY2018 | 62.6× | 9.59% |
| FY2017 | 57.2× | 22.80% |
| FY2016 | 46.5× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRCT PROCEPT BioRobotics Corporation compare | n/m |
| AORT Artivion, Inc. compare | n/m |
| CBLL CeriBell, Inc. compare | n/m |
| IART Integra LifeSciences Holdings Corporation | n/m |
| LMRI Lumexa Imaging Holdings, Inc. compare | n/m |
| QDEL QuidelOrtho Corporation compare | n/m |
| ENOV Enovis Corporation compare | n/m |
| TNDM Tandem Diabetes Care, Inc. compare | n/m |
| IRMD iRadimed Corporation compare | 48.5× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)